Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells

Cancer Biology and Therapy

Volumn 5, Issue 10, 2006, Pages 1304-1312

  Zhang, Tianqian ^a   Somasundaram, Rajasekharan ^a   Berking, Carola ^a   Caputo, Laura ^a   Van Belle, Patricia ^b   Elder, David ^b   Czerniecki, Brian ^c   Hotz, Susan ^b   Schuchter, Lynn ^d   Spitz, Francis R ^c   Berencsi, Klara ^a   Rani, Pyapalli ^a   Marincola, Francesco ^e   Qiu, Ruihua ^a   Herlyn, Dorothee ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apoptosis; Chemokine; Chemokine receptor; Chemotaxis; Cytotoxic T lymphocyte; Melanoma; Tumor immunology

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; STROMAL CELL DERIVED FACTOR 1;

ADULT; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 33751103138     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.10.3153     Document Type: Article

References (44)

1. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2:175-84.
2. Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med 2001; 2001:1-18.
3. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002; 13:143-54.
4. Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, Markert JM. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther 2005; 12:359-68.
5. Biragyn A, Kwak LW. Designer cancer vaccines are still in fashion. Nat Med 2000; 6:966-8.
6. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17:253-8.
7. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D. CXC chemokine ligand 12 (stromal cell-derived factor 1{alpha}) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol 2005; 174:5856-63.
8. Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D. Migration of cytotoxic T lymphocytes toward melanoma cells in threedimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol 2006; 36:457-67.
9. Somasundaram R, Robbins P, Moonka D, Loh E, Marincola F, Patel A, Guerry D, Herlyn D. CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells. Int J Cancer 2000; 85:253-9.
10. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002; 527:255-62.
11. Somasundaram R, Swoboda R, Caputo L, Lee A, Jackson N, Marincola FM, Guerry D, Herlyn D. A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma. Int J Cancer 2003; 104:362-8.
12. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996; 156:3678-86.
13. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003; 199:221-8.
14. Woodland DL, Dutton RW. Heterogeneity of CD4(+) and CD8(+) T cells. Curr Opin Immunol 2003; 15:336-42.
15. Friedl P, Entschladen F, Conrad C, Niggemann B, Zanker KS. CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers and locomotion. Eur J Immunol 1998; 28:2331-43.
16. Rao WH, Hales JM, Camp RD. Potent costimulation of effector T lymphocytes by human collagen type I. J Immunol 2000; 165:4935-40.
17. Murakami S, Okada H. Lymphocyte-fibroblast interactions. Crit Rev Oral Biol Med 1997; 8:40-50.
18. Aiba S, Nakagawa S, Hara M, Tomioka Y, Deguchi M, Tagami H. Cultured murine dermal cells can function like thymic nurse cells. J Invest Dermatol 1994; 103:162-7.
19. Crowston JG, Salmon M, Khaw PT, Akbar AN. T-lymphocyte-fibroblast interactions. Biochem Soc Trans 1997; 25:529-31.
20. Maas-Szabowski N, Stark HJ, Fusenig NE. Keratinocyte growth regulation in defined organotypic cultures through IL-1-induced keratinocyte growth factor expression in resting fibroblasts. J Invest Dermatol 2000; 114:1075-84.
21. Kruger K, Buning C, Schriever F. Activated T lymphocytes bind in situ to stromal tissue of colon carcinoma but lack adhesion to tumor cells. Eur J Immunol 2001; 31:138-45.
22. Maaser K, Wolf K, Klein CE, Niggemann B, Zanker KS, Brocker EB, Friedl P. Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell 1999; 10:3067-79.
23. Binnerts ME, van Kooyk Y, Simmons DL, Figdor CG. Distinct binding of T lymphocytes to ICAM-1, -2 or -3 upon activation of LFA-1. Eur J Immunol 1994; 24:2155-60.
24. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382:833-5.
25. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382:829-33.
26. Rollins BJ. Chemokines. Blood 1997; 90:909-28.
27. Syrbe U, Siveke J, Hamann A. Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin Immunopathol 1999; 21:263-85.
28. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002; 3:35-43.
29. Banner BF, Savas L, Woda BA. Expression of adhesion molecules in the host response to colon carcinoma. Ultrastruct Pathol 1995; 19:113-8.
30. Starnes HF, Jr. Biological effects and possible clinical applications of interleukin 1. Semin Hematol 1991; 28:34-41.
31. Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001; 167:6869-76.
32. Wei WZ, Miller B, Gutierrez RM. Inhibition of tumor growth by peptide specific cytotoxic T lymphocytes in a three-dimensional collagen matrix. J Immunol Methods 1997; 200:47-54.
33. Jacobs N, Moutschen MP, Franzen-Detrooz E, Boniver V, Boniver J, Delvenne P. Organotypic culture of HPV-transformed keratinocytes: a model for testing lymphocyte infiltration of (pre)neoplastic lesions of the uterine cervix. Virchows Arch 1998; 432:323-30.
34. Tasaki A, Yamanaka N, Kubo M, Matsumoto K, Kuroki H, Nakamura K, Nakahara C, Onishi H, Kuga H, Baba E, Tanaka M, Morisaki T, Katano M. Three-dimensional two-layer collagen matrix gel culture model for evaluating complex biological functions of monocyte-derived dendritic cells. J Immunol Methods 2004; 287:79-90.
35. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62:1832-7.
36. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 1998; 273:4282-7.
37. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999; 154:1125-35.
38. Dunussi-Joannopoulos K, Zuberek K, Runyon K, Hawley RG, Wong A, Erickson J, Herrmann S, Leonard JP. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood 2002; 100:1551-8.
39. Nomura T, Hasegawa H, Kohno M, Sasaki M, Fujita S. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes. Int J Cancer 2001; 91:597-606.
40. Clemente GC, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-10.
41. Fischer WH, Straten PT, Terheyden P, Becker JC. Function and dysfunction of CD4+ T cells in the immune response to melanoma. Cancer Immunol Immunother 1999; 48:363-70.
42. Halliday GM, Patel A, Hunt MJ, Tefany FJ, Barneston RS. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 1995; 19:352-8.
43. Mathiot C, Robin E, Gey A, Weng X, Dorval T, Pouillart P, Sastre X, Zerbib M, Hamelin JP, Salmon R, Durand JC, Brandely M, Fridman WH. Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with melanoma and other metastatic cancers. Eur J Cancer 1992; 28:345-50.
44. Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64:7697-701.